The benefits of Robotic Magnetic Navigation (RMN) have been validated by >100 leading hospitals globally treating >100,000 patients. The improvements in outcomes have been demonstrated with scientific rigor in hundreds of scientific publications.

Calculate Your ROI
Incremental Annual Procedures with Robot*
Average Reimbursement (USD)2
Total Annual Procedures with Robot
X-Ray / Procedure (min)
Average Procedure Time (hr)
* Primary drivers of practice growth include: treating complex arrhythmias that are otherwise not good candidates for catheter ablation, attracting new patients and improved lab efficiency.
Net Present Value
Payback Period
Internal Rate of Return
Other Considerations
The numbers above do not consider the human, organizational, and ultimately financial benefits of improving patient care and staff safety.
Patients
Physicians

Avoided Perforations
(10 Years)

Hours Standing Wearing Lead Spared (10 Years)

Avoided Other Major Complications (10 Years)

Minutes of Radiation Exposure Avoided (10 Years)
Patients
Avoided Perforations
(10 Years)
Avoided Other Major Complications
(10 Years)
Physicians
Hours Standing Wearing Lead Spared
(10 Years)
Minutes of Radiation Exposure Avoided
(10 Years)
This data is illustrative of potential benefits of a Robotic EP practice but no such benefit is guaranteed and clinical experience may vary widely. Clinical data is available on file at Stereotaxis or at www.RoboticEP.com/Clinical-Data. Cardiac perforation rates reflect data from known published controlled studies of Stereotaxis technology (3,265 patients in total). Other major adverse events reflects average complication rates from all published head-to-head studies (4,675 patients in total) minus perforation rates. Data updated 2020.
Discuss your institution’s ROI for building a Robotic EP program.




- Data on file as shown on https://www.roboticep.com/clinical-data/
- Based on an average reimbursement level of $34,834 determined using 2020 national-average Medicare reimbursement rate of $23,223 (DRG code 273) and assumed national-average private payor rate of $46,446. Patient volume modeled as 50% Medicare and 50% private payor. Assumed premium of 100% for private payors supported by various literature:
- Lopez E, et al.. How Much More Than Medicare Do Private Insurers Pay? A Review of the Literature. The Henry J. Kaiser Family Foundation. https://www.kff.org/. Published April 15, 2020.
- Chapin, et al. Private Health Plans Pay Hospitals Much More Than What Medicare Would Pay. RAND Corporation. https://www.rand.org/. Published May 9, 2019.
- Roguin A, Goldstein J, Bar O, Goldstein JA. Brain and neck tumors among physicians performing interventional procedures. Am J Cardiol. 2013;111(9):1368-72.
- Vano E, Leiman NJ, Duran A, Romano-Miller M, Rehani MM. Radiation-associated lens opacities in catheterization personnel: results of a survey and direct assessments. J Vasc Interv Radiol. 2013;24(2):197-204
- Klein LW, Tra Y, Garratt KN, Powell W, Lopez-Cruz G, Chambers C, et al. Occupational health hazards of interventional cardiologists in the current decade: Results of the 2014 SCAI membership survey. Catheter Cardiovasc Interv. 2015;86(5):913-24
- Turagam MK, Atkins D, Tung R, Mansour M, Ruskin J, Cheng J, et al. A meta-analysis of manual versus remote magnetic navigation for ventricular tachycardia ablation. J Interv Card Electrophysiology. 2017 Sept;49(3):227-235.
Stereotaxis Intended Use Statements, United States Labeling:
The Genesis RMN® and Niobe® ES Systems are intended to navigate compatible magnetic devices through tissue to designated target sites in the right and left heart, coronary vasculature, neurovasculature, and peripheral vasculature by orienting the device tip in a desired direction. The Cardiodrive® Catheter Advancement System (CAS) is intended to automatically advance and retract compatible magnetic electrophysiology (EP) mapping and ablation catheters inside a patient’s heart when used in conjunction with a Stereotaxis magnetic navigation system. The Cardiodrive System is not intended to advance the EP mapping and ablation catheters through the coronary vasculature or the coronary sinus.
Consult the associated product labeling for the Indications for Use and instructions of other devices used in conjunction with Stereotaxis products.
Cardiodrive and Niobe are trademarks of Stereotaxis, Inc., registered in the United States, the European Community, and Japan. Genesis RMN is a trademark of Stereotaxis, Inc., registered in the United States.